P3.18.39 PRESERVE-003: A Phase 3 Study of Gotistobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 InhibitorsTengfei Li, Mark A. Socinski, B.C. Cho et al.|Journal of Thoracic Oncology|2025Cited by 1